Skip to content
Markets News
Earnings1 min read

Emcure Jumps as FY27 Revenue Growth Outlook Tops 20%

Makkler Newsroom
November 4, 2026 · Based on reporting by The Economic Times, Business Standard

The drugmaker raised its growth guidance after second-quarter revenue rose 24.2%, with international sales leading the increase.

Key takeaways

  • Emcure raised its FY27 revenue growth outlook to more than 20%, from the mid-teens.
  • Second-quarter consolidated revenue increased 24.2% year on year to ₹2,820.4 crore.
  • International sales rose 34.5% and accounted for 59% of consolidated revenue.

Emcure Pharmaceuticals raised its FY27 revenue growth outlook to more than 20%, from the mid-teens, after reporting a 24.2% year-on-year increase in second-quarter revenue. The shares reached ₹2,180.80 on the BSE during Wednesday’s trading.

At 07:47 UTC, the shares traded at ₹2,174.20 on the NSE, up 10% from the previous close. Emcure reported consolidated net profit of ₹325.5 crore, up 33.7%, while EBITDA rose 23.6% to ₹587.8 crore, according to Business Standard.

International sales climbed 34.5% to ₹1,665.2 crore and made up 59% of consolidated revenue. Domestic revenue grew 12% to ₹1,155.3 crore, led by women’s health, cardio-metabolics and central nervous system products, the report said.

Management also raised its outlook for EBITDA margin improvement by 100 basis points, to the upper end of its previous guidance. Emcure said it expects international growth to continue, supported by Amphotericin B, new product launches and its existing business.

Jefferies said the results beat its revenue, EBITDA and profit estimates by 7% to 10%, driven by stronger international growth. The brokerage raised its price target to ₹2,500 from ₹2,320.

Topics

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.